Anti-Mouse IL-2 (Clone JES6-1A12) - Purified
Code | Size | Price |
---|
LEI-I-1041-0.5mg | 0.5 mg | £262.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: JES6-1A12
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Mouse IL-2 (>98%)
Long Description:
IL-2 is a 17.2 kD cytokine signaling protein that is the regulator of the proliferative and suppressive phases of the immune response, and stimulates growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes. It functions as a primary regulator of T cell homeostasis. Il-2 regulates the activities of white blood cells and plays a role in the immune system via ?self? and ?non-self? discrimination. IL-2 is a prime candidate in immunotherapeutics for both increasing T cell levels/function and for augmenting vaccine-elicited viral-specific T cell responses. IL-2 signal can be transduced via 3 different signaling pathways that include the JAK-STAT, PI3K/Akt/mTOR and MAPK/ERK pathways. Aldesleukin is a form of recombinant interleukin-2 for the treatment of cancers including malignant melanoma and renal cell cancer. Furthermore, there is additional therapeutic potential for IL-2 mAb use with transplants and autoimmune disease.
NCBI Gene:
16183
Target:
IL-2
References
1. Schachter, J. et al. (2009) Cytotherapy 11: 206 2. Sodora, DL. et al. (2009) Curr HIV Res. 7: 83 3. Alcocer-Varela, J. et al. (2009) Autoimmun Rev. 9(1):34-9.
Related Products
Product Name | Product Code | Supplier | Anti-Mouse IL-2 (Clone JES6-1A12) - DyLight® 550 | LEI-I-1088 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-Mouse IL-2 (Clone JES6-1A12) - DyLight® 594 | LEI-I-1089 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - FITC | LEI-I-1093 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - Biotin | LEI-I-1094 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - APC | LEI-I-1095 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - PE | LEI-I-1096 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - DyLight® 594 | LEI-I-1100 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Mouse IL-2 (Clone JES6-5H4) - DyLight® 650 | LEI-I-1101 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||